: Background: The role of minimal extrathyroidal extension (mETE) as a risk factor for persistent papillary thyroid carcinoma (PTC) is still debated. The aims of this study were to assess the clinical impact of mETE as a predictor of worse initial treatment response in PTC patients and to verify the impact of radioiodine therapy after surgery in patients with mETE. Methods: We reviewed all records in the Italian Thyroid Cancer Observatory database and selected 2237 consecutive patients with PTC who satisfied the inclusion criteria (PTC with no lymph node metastases and at least 1 year of follow-up). For each case, we considered initial surgery, histological variant of PTC, tumor diameter, recurrence risk class according to the American Thyroid Association (ATA) risk stratification system, use of radioiodine therapy, and initial therapy response, as suggested by ATA guidelines. Results: At 1-year follow-up, 1831 patients (81.8%) had an excellent response, 296 (13.2%) had an indeterminate response, 55 (2.5%) had a biochemical incomplete response, and 55 (2.5%) had a structural incomplete response. Statistical analysis suggested that mETE (odds ratio [OR] 1.16, p = 0.65), tumor size >2 cm (OR 1.45, p = 0.34), aggressive PTC histology (OR 0.55, p = 0.15), and age at diagnosis (OR 0.90, p = 0.32) were not significant risk factors for a worse initial therapy response. When evaluating the combination of mETE, tumor size, and aggressive PTC histology, the presence of mETE with a >2 cm tumor was significantly associated with a worse outcome (OR 5.27 [95% confidence interval], p = 0.014). The role of radioiodine ablation in patients with mETE was also evaluated. When considering radioiodine treatment, propensity score-based matching was performed, and no significant differences were found between treated and nontreated patients (p = 0.24). Conclusions: This study failed to show the prognostic value of mETE in predicting initial therapy response in a large cohort of PTC patients without lymph node metastases. The study suggests that the combination of tumor diameter and mETE can be used as a reliable prognostic factor for persistence and could be easily applied in clinical practice to manage PTC patients with low-to-intermediate risk of recurrent/persistent disease.

Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4) / Forleo, Raffaella; Grani, Giorgio; Alfò, Marco; Zilioli, Valentina; Giubbini, Raffaele; Zatelli, Maria Chiara; Gagliardi, Irene; Piovesan, Alessandro; Ragni, Alberto; Morelli, Silvia; Puxeddu, Efisio; Pagano, Loredana; Deandrea, Maurilio; Ceresini, Graziano; Torlontano, Massimo; Puligheddu, Barbara; Antonelli, Alessandro; Centanni, Marco; Fugazzola, Laura; Spiazzi, Giovanna; Monti, Salvatore; Rossetto, Ruth; Monzani, Fabio; Tallini, Giovanni; Crescenzi, Anna; Sparano, Clotilde; Bruno, Rocco; Repaci, Andrea; Tumino, Dario; Pezzullo, Luciano; Lombardi, Celestino Pio; Ferraro Petrillo, Umberto; Filetti, Sebastiano; Durante, Cosimo; Castagna, Maria Grazia. - In: THYROID. - ISSN 1050-7256. - 31:12(2021), pp. 1814-1821-1821. [10.1089/thy.2021.0248]

Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4)

Ceresini, Graziano;
2021

Abstract

: Background: The role of minimal extrathyroidal extension (mETE) as a risk factor for persistent papillary thyroid carcinoma (PTC) is still debated. The aims of this study were to assess the clinical impact of mETE as a predictor of worse initial treatment response in PTC patients and to verify the impact of radioiodine therapy after surgery in patients with mETE. Methods: We reviewed all records in the Italian Thyroid Cancer Observatory database and selected 2237 consecutive patients with PTC who satisfied the inclusion criteria (PTC with no lymph node metastases and at least 1 year of follow-up). For each case, we considered initial surgery, histological variant of PTC, tumor diameter, recurrence risk class according to the American Thyroid Association (ATA) risk stratification system, use of radioiodine therapy, and initial therapy response, as suggested by ATA guidelines. Results: At 1-year follow-up, 1831 patients (81.8%) had an excellent response, 296 (13.2%) had an indeterminate response, 55 (2.5%) had a biochemical incomplete response, and 55 (2.5%) had a structural incomplete response. Statistical analysis suggested that mETE (odds ratio [OR] 1.16, p = 0.65), tumor size >2 cm (OR 1.45, p = 0.34), aggressive PTC histology (OR 0.55, p = 0.15), and age at diagnosis (OR 0.90, p = 0.32) were not significant risk factors for a worse initial therapy response. When evaluating the combination of mETE, tumor size, and aggressive PTC histology, the presence of mETE with a >2 cm tumor was significantly associated with a worse outcome (OR 5.27 [95% confidence interval], p = 0.014). The role of radioiodine ablation in patients with mETE was also evaluated. When considering radioiodine treatment, propensity score-based matching was performed, and no significant differences were found between treated and nontreated patients (p = 0.24). Conclusions: This study failed to show the prognostic value of mETE in predicting initial therapy response in a large cohort of PTC patients without lymph node metastases. The study suggests that the combination of tumor diameter and mETE can be used as a reliable prognostic factor for persistence and could be easily applied in clinical practice to manage PTC patients with low-to-intermediate risk of recurrent/persistent disease.
Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4) / Forleo, Raffaella; Grani, Giorgio; Alfò, Marco; Zilioli, Valentina; Giubbini, Raffaele; Zatelli, Maria Chiara; Gagliardi, Irene; Piovesan, Alessandro; Ragni, Alberto; Morelli, Silvia; Puxeddu, Efisio; Pagano, Loredana; Deandrea, Maurilio; Ceresini, Graziano; Torlontano, Massimo; Puligheddu, Barbara; Antonelli, Alessandro; Centanni, Marco; Fugazzola, Laura; Spiazzi, Giovanna; Monti, Salvatore; Rossetto, Ruth; Monzani, Fabio; Tallini, Giovanni; Crescenzi, Anna; Sparano, Clotilde; Bruno, Rocco; Repaci, Andrea; Tumino, Dario; Pezzullo, Luciano; Lombardi, Celestino Pio; Ferraro Petrillo, Umberto; Filetti, Sebastiano; Durante, Cosimo; Castagna, Maria Grazia. - In: THYROID. - ISSN 1050-7256. - 31:12(2021), pp. 1814-1821-1821. [10.1089/thy.2021.0248]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2907329
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact